NasdaqGS:JAZZPharmaceuticals
How Boehringer Ingelheim Oncology Collaboration Could Shape Jazz Pharmaceuticals' (JAZZ) Dual HER2 Strategy
In January 2026, Boehringer Ingelheim announced a clinical collaboration with Jazz Pharmaceuticals to test a combination of zongertinib and zanidatamab in a Phase 1b cohort for HER2-positive breast cancer within the ongoing Beamion-BCGC1 trial.
This partnership links two recently approved HER2-targeted therapies from different cancer settings, aiming to generate data on dual HER2 blockade that could shape future treatment options across HER2-driven tumors.
Next, we’ll examine how this dual...